Proactive Investors - Run By Investors For Investors

NetScientific rockets as ProAxsis sees positive early trial data for NEATstik lung disease test

The data, published in the peer-reviewed European Respiratory Journal, found that NEATstik was able to replicate the results of existing tests for chest infections within only ten minutes
Lungs
NetScientific holds a 56.5% stake in ProAxsis

NetScientific PLC (LON:NSCI) shares soared on Friday after its portfolio firm, ProAxsis, received positive early data from a clinical trial of its NEATstik lung disease test.

The AIM-listed firm, which commercialises healthcare IPs and holds a 56.5% stake in ProAxsis, said the data had come from BRIDGE, a major three-year study into bronchiectasis, a condition that causes abnormal widening of the lungs, involving over 1000 patients and funded by the British Lung Foundation and the European Respiratory Society.

READ: NetScientific to focus on extending lifespan as CEO reiterates confidence in portfolio firms

The data, published in the peer-reviewed European Respiratory Journal, found that NEATstik was able to replicate the results of existing tests for chest infections within only ten minutes, meaning the test could potentially support appropriate usage of antibiotic therapy.

"This encouraging data published in the renowned European Respiratory Journal demonstrates ProAxsis' ability to monitor bacterial infections in real time in patients suffering from lung diseases”, said Ian Postlethwaite, chief executive of NetScientific.

“NEATstik has the potential to provide clinicians with a test identifying those at risk of further exacerbations providing more targeted care. We believe that ProAxsis has the potential to become a significant player in the growing point-of-care respiratory testing market."

In early deals, NetScientific shares were up 52.7% at 13p.

--Adds share price--

View full NSCI profile View Profile

Netscientific PLC Timeline

Related Articles

test tubes
May 02 2019
Proactive takes a closer look at an innovative drugs company that has largely flown under the radar
A woman with severe depression
April 25 2019
The New York clinical-stage biopharmaceutical company has several drugs in the pipeline capable of generating hefty revenue
1550850611_CancerHeadline.jpg
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use